GlucoTrack Enters Sales Agreement with Dawson James SecuritiesOn December 17, 2024, GlucoTrack, Inc. (NASDAQ:GCTK) announced the signing of an At-the-Market (ATM) sales agreement with Dawson James Securities, Inc. (“Dawson James”). The agreement invo

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read GlucoTrack’s 8K filing here.

About GlucoTrack

(Get Free Report)

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain.

Featured Stories